Human Anti-CD45 x Anti-Myosin Bispecific Antibody (IgG-IgG) (BSIG-H294)

Anti-CD45 x Anti-Myosin Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD45 and anti-Myosin parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can recruit stem cells to infarcted myocardium. It is designed for the research of Myocardial infarction therapy.

Datasheet INQUIRY

Specifications

Targets

CD45 & Myosin

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Myocardial infarction

Targets

Target 1

CD45

Gene ID

5788

UniProt ID

P08575

Alternative Names

PTPRC; CD45; Cluster of differentiation 45; protein tyrosine phosphatase, receptor type C; LCA; LY5; B220; CD45; L-CA; T200; CD45R; GP180

Target 2

Myosin

Alternative Names

Myosin; ATP-dependent motor proteins

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human Anti-CD45 x Anti-Myosin Bispecific Antibody (IgG-IgG) (BSIG-H294). Click the button below to contact us or submit your feedback about this product.

Human Anti-CD45 x Anti-Myosin Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H294)

Specifications

Targets

Customer Reviews and Q&As